Table 2.

Effect of MDM2 inhibitor in primary AML and p53 status of the blasts




Annexin V+ in CD34+ fraction, % (in total MNC, %)


Patient no.
CD34+, %
DMSO*
1 μM*
5 μM*
10 μM*
Cell number reduction, %
p53 status
1   68   22 (27)   36 (41)   65 (67)   84 (82)   77   Wild-type  
2   96   9 (11)   49 (52)   81 (82)   87 (87)   94   Wild-type  
3   93   8 (11)   31 (32)   44 (47)   76 (74)   70   Wild-type  
4   79   17 (19)   39 (39)   76 (66)   91 (84)   91   Wild-type  
5   92   33 (32)   57 (61)   67 (72)   74 (78)   54   Wild-type  
6   44   10 (29)   33 (45)   85 (68)   97 (73)   93   Wild-type  
7   77   11 (18)   12 (17)   14 (20)   15 (21)   4   Mutant (R175G)  
8   65   26 (30)   71 (64)   89 (74)   94 (82)   96   Wild-type  
9   76   22 (20)   61 (54)   84 (76)   84 (81)   76   Wild-type  
10   29   32 (11)   61 (25)   92 (38)   98 (43)   68   Wild-type  
11   23   34 (26)   32 (32)   87 (64)   84 (68)   71   Wild-type  
12   4   27 (16)   40 (29)   64 (50)   79 (63)   60   Wild-type  
13   54   12 (14)   36 (35)   60 (52)   78 (63)   75   Wild-type  
14   11   30 (42)   58 (60)   81 (70)   91 (73)   62   Wild-type  
15   71   41 (34)   57 (45)   71 (67)   83 (72)   64   Wild-type  
16   92   18 (22)   60 (58)   70 (71)   88 (82)   76   Wild-type  
17   0   4 (15)   7 (10)   9 (15)   10 (17)   2   Mutant (r248q)  
18
 
98
 
16 (15)
 
21 (21)
 
86 (85)
 
97 (97)
 
84
 
Wild-type
 



Annexin V+ in CD34+ fraction, % (in total MNC, %)


Patient no.
CD34+, %
DMSO*
1 μM*
5 μM*
10 μM*
Cell number reduction, %
p53 status
1   68   22 (27)   36 (41)   65 (67)   84 (82)   77   Wild-type  
2   96   9 (11)   49 (52)   81 (82)   87 (87)   94   Wild-type  
3   93   8 (11)   31 (32)   44 (47)   76 (74)   70   Wild-type  
4   79   17 (19)   39 (39)   76 (66)   91 (84)   91   Wild-type  
5   92   33 (32)   57 (61)   67 (72)   74 (78)   54   Wild-type  
6   44   10 (29)   33 (45)   85 (68)   97 (73)   93   Wild-type  
7   77   11 (18)   12 (17)   14 (20)   15 (21)   4   Mutant (R175G)  
8   65   26 (30)   71 (64)   89 (74)   94 (82)   96   Wild-type  
9   76   22 (20)   61 (54)   84 (76)   84 (81)   76   Wild-type  
10   29   32 (11)   61 (25)   92 (38)   98 (43)   68   Wild-type  
11   23   34 (26)   32 (32)   87 (64)   84 (68)   71   Wild-type  
12   4   27 (16)   40 (29)   64 (50)   79 (63)   60   Wild-type  
13   54   12 (14)   36 (35)   60 (52)   78 (63)   75   Wild-type  
14   11   30 (42)   58 (60)   81 (70)   91 (73)   62   Wild-type  
15   71   41 (34)   57 (45)   71 (67)   83 (72)   64   Wild-type  
16   92   18 (22)   60 (58)   70 (71)   88 (82)   76   Wild-type  
17   0   4 (15)   7 (10)   9 (15)   10 (17)   2   Mutant (r248q)  
18
 
98
 
16 (15)
 
21 (21)
 
86 (85)
 
97 (97)
 
84
 
Wild-type
 

MNC, mononuclear cells.

*

Nutlin-3a concentrations. 0.1% DMSO treated cells served as controls.

The effect on cell viability was expressed as fraction of cells killed by Nutlin-3a in drug-treated versus 0.1% DMSO-treated cells.

or Create an Account

Close Modal
Close Modal